EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023
– Interim analysis of masked data shows EYP-1901 is well tolerated with no reported drug-related…
Sky City Acoma Casino Hotel Selects QCI Resorts™, the Unified Intelligence Platform for Resorts